Measles vaccination has been recommended after the second year following bone marrow transplant (BMT) in patients not receiving immunosuppressive drugs. During a measles outbreak, we vaccinated all patients after the first year of transplant, and conducted a prospective trial to evaluate safety, effectiveness and sustained immunity after early vaccination. Patients received attenuated virus vaccine between 9 and 18 months after BMT. A total of 51 patients were evaluated and 27 of them (52.9%) were receiving immunosuppressive drugs. Only mild adverse reactions were noted. Nine patients (17.6%) were susceptible (IgGp100 mIU/ml) at vaccination, and all seroconverted. In those immune at vaccination, a four-fold increase in measles IgG titers was found in one of 34 patients (2.9%) with specific IgGX200 mIU/ml compared to 14 of 17 (82.3%) with IgGo200 mIU/ml (Po 0.0001). Sustained immunity after 24 months was more likely to occur in patients with specific IgG levelsp200 or X500 mIU/mL (83.4 and 100%, respectively) in comparison to patients with 200oIgGo499 mIU/ml at vaccination (50%; P ¼ 0.017). We conclude that even though early measles vaccination is safe, few patients are susceptible on day þ 365 and this strategy should be reserved for epidemic situations posing significant threat for the patients.
long-term immunity
The loss of specific antibody responses to measles in patients submitted to allogeneic and autologous bone marrow transplant (BMT) has been consistently demonstrated. [1] [2] [3] A recently published study demonstrated that younger age, acute GVHD and especially pre-transplant vaccination to measles were risk factors for losing immunity to measles. 4 Thus, a reimmunization program is necessary to ensure immunity, and measles vaccination has been recommended and administered following the second year of transplant in patients not receiving immunosuppressive drug treatments. 1, [5] [6] [7] [8] [9] During a 1997 measles outbreak in the city of Sa˜o Paulo, eight BMT recipients acquired measles; seroepidemiological data from this population revealed that around 45% of BMT recipients were susceptible to measles after the first year of transplantation. Extending measles vaccination to all BMT patients after day þ 365 was the strategy successfully adopted to avoid new cases of measles infection during the outbreak. 3 As a consequence of these events, we conducted a prospective trial to evaluate the safety, serological efficacy and long-term immunity provided by measles vaccination administered 1 year after BMT for all patients, including those receiving immunosuppressive drugs.
Patients and methods

Patient population
From August 1997 to August 1999, all BMT patients alive on day þ 365 were invited to participate in the study protocol. In total, 177 myeloablative transplants were performed during this period. Of these, 80 patients died before day þ 365, 28 returned to their place of origin or were lost from the sample follow-up, and information on measles vaccination in five patients who died after the first year was not available. These patients were excluded from the study. Among the remaining 64 patients, 61 received early measles immunization and three were not vaccinated owing to severe complications and hospitalization around day þ 365. All allogeneic transplants had bone marrow as the source of stem cells. The conditioning regimen included busulfan and melphalan in 27 patients (52.9%), TBI and cyclophosphamide in 12 (23.5%), busulfan and cyclophosphamide in 11 (21.5%), and melphalan and fludarabine in one patient (1.9%).
Measles vaccination
Patients were given written information regarding adverse reactions to measles vaccine. All patients received a printed form to mark any adverse effect after vaccination and those not receiving immunosuppressive drugs were allowed to report side effects by phone call. Patients receiving immunosuppression and considered at greater risk of developing adverse reactions were told to report adverse effects personally. Moreover, since in our BMT Program cytomegalovirus antigenemia surveillance is kept in patients with chronic GVHD, these patients were generally seen weekly during follow-up. To better evaluate the occurrence of adverse reactions following measles vaccination, other vaccines supposed to start on day þ 365 were postponed to 1 month after measles vaccine.
The patients received one dose of MMR II s (MSD). No patient was receiving intravenous immunoglobulin. Informed consent was obtained from all patients and the study was approved by the Ethics and Research Committee of the Hospital das Clı´nicas of the University of Sa˜o Paulo Medical School.
Serology
Blood samples for serology were taken immediately before vaccination and 2, 6, 12 and 24 months after measles vaccine. Measles IgG antibodies were detected using an inhouse EIA. Standard serum (National Institute for Biological Standards and Control, Hertford, England) was included in each set of tests. Antibody titers were expressed in mIU/ml, calculated employing a linear regression analysis. Patients with EIA titers 4100 mIU/ ml were considered immune to measles. 10 Response to vaccination was defined as seroconversion or a four-fold increase in IgG titers 2 months after vaccination.
IgG avidity test
The IgG avidity test was performed using the urea method to characterize the type of infection, primary or secondary. Briefly, after incubation with diluted serum for 1 h at 371C, the wells were washed twice with PBST. Half the wells were soaked for 10 min with 7 M urea in phosphate-buffered saline containing 0.05% Tween 80 (PBST) and half with PBST without urea. After two additional washes, the antibodies were detected by conventional EIA. The result for each serum, expressed as DOD, was obtained by subtracting the absorbance of the control antigen from the absorbance of the measles virus antigen. The avidity index was calculated by (DOD with urea/DOD without urea) Â 100 and a value of 30% or less was considered indicative of primary infection. 10 
Inclusion criteria
The inclusion criteria for data analysis were: (1) A proven measles vaccination (official vaccination card) between 9 and 18 months after BMT. (2) Blood samples taken immediately before and 2 months after vaccination.
Statistical analysis
Statistical significance was evaluated using the Chi-squared test. The probability of loss of measles antibodies after vaccination was estimated by survival analysis (KaplanMeier). Loss of measles immunity was considered the event, and persistence of measles immunity was censored at the end of follow-up or on the patient's death.
Results
A total of 61 patients were vaccinated. No moderate or severe adverse reactions were reported by any patient. Five patients reported myalgia and one patient presented lowgrade fever (o38.51C). Since a measles-mumps-rubella vaccine was used, such unspecific and mild adverse reactions could be caused by any of the components of the administered vaccine. No interference of vaccination was seen in the outcome of chronic GVHD. Among the 51 patients who fulfilled the inclusion criteria, the median time to vaccine administration was 12 months, ranging from 9 to 18 months after BMT. Vaccination date was flexible to coincide with the routine visits. Thus, 28 patients (54.9%) were vaccinated between the 11th and 13th month of transplantation, 15 patients (29.4%) were vaccinated between the 13th and 18th month and the remaining eight patients (15.7%) received the vaccine before the 11th month. This latter group constituted children less than 14 years old, five of them not receiving immunosuppressive drugs, who were urged to return home. At this time, the epidemic had reached most of the States of Brazil and the medical decision was to anticipate the vaccine in those children.
A total of 27 patients (52.9%) were receiving immunosuppressive drugs. In all, 12 patients were receiving Cyclosporine A (CyA), 11 were on an alternate protocol with CyA and Prednisone, two were receiving Prednisone alone (at least 20 mg/day) and two were receiving Mycophenolate Mofetil (MMF). Extensive chronic GVHD was seen in 22 patients and localized chronic GVHD in five patients. The patients' characteristics are provided in Table 1 .
Nine allogeneic BMT recipients (17.6%) were susceptible (IgGp100 mIU/ml) at vaccination, and all seroconverted. Seven patients (77.7%) were receiving immunosuppressive drugs at the time of vaccination. IgG avidity index and sustained immunity at 12 months after vaccination in this group is shown in Table 2 .
In 17 patients with specific IgG levels lower than 200 mIU/ml, seroconversion or a four-fold increase in IgG titers was found in 14 patients (82.3%). In contrast, only one of the 34 patients (2.9%) with specific IgG levels higher than 200 mIU/ml at vaccination showed a four-fold rise in IgG levels ( Univariate analysis demonstrated that the use of immunosuppressive drugs did not interfere in the response to vaccination (Table 3 , P ¼ 0.33, Yates corrected test).
The avidity index of IgG antibodies could be estimated in only 11 patients who had available serum samples taken up to 2 months after vaccination. All patients showed high avidity IgG antibodies, indicating secondary immune response. Four of the 11 patients were susceptible to measles.
Survival analysis showed that after 24 months of early measles vaccination, the probability of sustained immunity was significantly lower in patients with specific IgG levels between 200 and 499 mIU/ml at vaccination (51.3%) in comparison to patients with IgG levels lower than 200mIU/ ml or higher than 500 mIU/ml at vaccination (83.3 and 100%, respectively; P ¼ 0.017; Figure 1) .
The overall probabilities of sustained immunity after early measles vaccination were 94.5, 89.8 and 78.6% at 12, 18 and 24 months after vaccination, respectively.
Discussion
Measles infection can represent a threat to immunocompromised patients. As a consequence of the potential risk of vaccine virus replication and dissemination in immunocompromised subjects, 9 live, attenuated virus vaccines have been recommended only after the second year of transplant for patients not receiving immunosuppressive drugs. 5, 6, 8, 9 Although anecdotal reports have mentioned the use of measles vaccination before the second year of bone marrow transplant, 12, 13 few data are available concerning the safety and effectiveness of measles vaccination during this period. 13 In the present study, we demonstrated that an attenuated measles virus vaccine is safe for use before the second year after bone marrow transplant, even in patients receiving immunosuppressive drugs.
Seven of the nine (77.7%) susceptible allogeneic BMT recipients were receiving immunosuppressive drugs, all seroconverted, and no severe or moderate adverse reactions related to the measles vaccine were reported. Other authors have recently reported the safety of measles vaccination prior to the second year of transplant. However, in that series, the vaccine was used only in patients without chronic GVHD and not receiving immunosuppressive drugs for at least 3 months. 13 If a boost, not a primary response, occurs after vaccination, replication of the attenuated virus should be limited by the rapid increase in specific antibodies, and consequently, the risk of vaccine complication will be minimal. All susceptible, unvaccinated BMT recipients who acquired measles during the Sa˜o Paulo outbreak in 1997 exhibited high avidity antibodies during the acute phase of measles, indicating a secondary immune response. 3 Likewise, in the present series, all of the 11 patients tested for the avidity of IgG antibodies showed high avidity antibodies 2 months after vaccination, including those who were susceptible to measles at vaccination. Although the avidity test was performed in only 11 patients, we would like to stress that secondary responses seems to be the rule after measles vaccination in BMT recipients. The stimulation of precommitted memory B cells transferred from the donor may explain the lack of significant adverse reactions in the early vaccination schedule. Other authors have demonstrated that either T-or B-cell immunity persists after BMT and can modify the response to measles vaccine. 14 Within the context of a measles outbreak, this information is relevant to establishing vaccination as a safe alternative to control measles transmission among susceptible BMT recipients, including those before the second year of transplant or those receiving immunosuppressive drugs.
On the other hand, in patients considered immune at vaccination, we found that the response to vaccination (IgG titer increase) was inversely related to the IgG level at vaccination. A four-fold increase in IgG titers was more likely to occur in patients with IgG titers lower than 200 mIU/ml compared to those with IgG titers X200 mIU/ ml at vaccination (82.3 vs 2.9%, respectively). These data clearly demonstrate that the presence of specific IgG antibodies (4200 mIU/ml) suppresses attenuated virus replication. The use of immunosuppressive drugs did not seem to interfere in the response to the vaccine in the present series.
Although early measles vaccination proved to be safe, around 80% of recipients are immune to measles 1 year after BMT 3 and consequently, early vaccination is clearly unjustified in these patients. Moreover, since only 3% of patients with IgG titers greater than 200 mIU/mL at vaccination will show a four-fold increase in IgG titers, serological screening should precede measles vaccination at this time, which is costly.
Likewise, long-term immunity elicited by early vaccination strategy is more likely to be related to the strength of response at vaccination, which occurs more frequently in susceptible patients or those with IgG titers between 100 and 200 mIU/ml at vaccination. Thus, the 2 years' sustained immunity of patients with IgG titers greater than 500 mIU/ml at vaccination (showed in figure one) cannot be attributed to early vaccination strategy, but simply reflects the time taken for measles antibodies to extinguish after BMT.
We also observed that early vaccination would not particularly benefit those patients with measles IgG titers between 200 and 499 mIU/ml at vaccination. At first sight, it seems paradoxical that the duration of immunity at the 24th month is more sustained in those with specific IgG titers below 200 mIU/ml at vaccination than those with specific IgG titers between 200 and 499 mIU/ml. However, the presence of specific IgG antibodies at these levels suppresses attenuated virus replication and the vaccine will not elicit a boost response. Measles immunity will inexorably wane over time and an increasing number of susceptible patients will be expected shortly, creating the ideal condition for the occurrence of epidemics, once the wild virus is introduced into the community.
This study, conducted in the very particular situation constituted by the 1997 measles outbreak in the city of Sa˜o Paulo, demonstrates that measles vaccination is safe in BMT recipients receiving immunosuppressive drugs and therefore can be recommended whenever a susceptible patient is identified. Moreover, the strategy of extending vaccination to all BMT recipients was effective in interrupting the transmission of measles. The epidemic started in February 1997, peaked in August and lasted at least 1 year. Eight cases of measles were diagnosed in our BMT recipients from May to July. 3 In August, we started vaccination and since then, no more cases of measles were seen in BMT recipients.
Our data also suggest that serological screening every 6 months is prudent during the first 2 years of transplantation, especially in those patients most likely to lose their measles immunity over a short period of time (IgG titers p200 mIU/ml).
We conclude that measles attenuated virus vaccine before the second year of BMT is safe, but the level of persisting antibodies influences vaccine response. Early vaccination strategy should not be recommended routinely but reserved for epidemic situations posing significant threat for the patients. However, current recommendations should safely consider the inclusion of susceptible patients receiving immunosuppressive drugs. 
